

# A Pilot Study To Evaluate The Autism Co-Morbid Risk Score

Department of Pediatrics, University of Chicago  
Department of Medicine, University of Chicago

## CONTENTS

|                   |  |           |
|-------------------|--|-----------|
| <b>1</b>          | <b>Cover Page</b>                          | <b>1</b>  |
| <b>2</b>          | <b>Specific Aims</b>                       | <b>2</b>  |
| <b>3</b>          | <b>Research Strategy</b>                   | <b>1</b>  |
| 3.1               | Significance . . . . .                     | 1         |
| 3.2               | Innovation . . . . .                       | 3         |
| 3.3               | Approach . . . . .                         | 3         |
| 3.4               | Study Interventions and Measures . . . . . | 12        |
| <b>References</b> |  | <b>13</b> |

## ABBREVIATIONS

|                  |   |
|------------------|---|
| ASD              | Autism Spectrum Disorder                                |
| MCHAT-F          | Modified Checklist for Autism in Toddlers with Followup |
| ADOS /<br>ADOS-2 | Autism Diagnostic Observation Schedule                  |
| ABA              | Applied Behavior Analysis                               |
| ACoR             | Autism Comorbid Risk                                    |

## 1. COVER PAGE

## 2. SPECIFIC AIMS

Early diagnosis of Autism Spectrum Disorder (ASD) and the timely intervention is widely recognized as critical for achieving improved cognitive, behavioral and social outcomes.<sup>[1]</sup> While a diversity of factors are implicated,<sup>[2]–[5]</sup> the etiology of Autism is still unknown. With no laboratory tests for ASD, and despite advances from widespread adoption of screening with standardized checklists at 18 and 24 months of age, the median age of diagnosis remains over 4 years. Starting with a positive initial screen, a clinical diagnosis of ASD is a frustrating multi-step process spanning 3 months to 1 year, often delaying time-critical intervention. One obvious source of these delays is the vast number of false positives encountered in the current initial screening tools. For example, the M-CHAT/F, the most widely used screen,<sup>[1], [6]</sup> produces about over 85 false positives out of every 100 flagged for diagnostic evaluation, significantly inflating wait times<sup>[5]</sup> especially in rural and underserved communities. Further, current screening tools are sensitive to language barriers and cultural issues, and are particularly ineffective for children with milder symptoms with average or above-average cognitive abilities until about school age,<sup>[1], [7]</sup> often due to a “wait and see” approach adopted at the primary care.

In this study, we plan to develop and validate the efficacy of machine inferred **digital biomarkers** for autism, mined automatically from past medical encounters. Using individual diagnostic codes already present in individual patient files, we plan to engineer a reliable risk estimator (**ASD Co-morbid Risk: ACoR**) enabled by novel machine learning algorithms, and compare its effectiveness againsts existing screening tools such as M-CHAT/F. Our rationale is informed by the extensively documented comorbidities of ASD ranging from dysregulation of immune pathways such as eczema, allergies, asthma, as well as ear and respiratory infections, gastrointestinal problems, developmental issues, severe headaches, migraines, and seizures.<sup>[8], [9]</sup> While ASD presentation is highly variable, sophisticated pattern recognition on the longitudinal history of diagnostic codes is expected to reveal uncharted associations that allow precise screening for at-risk patients. Orthogonal to questionnaire based detection of behavioral signals, the proposed tool potentially reduces socio-economic, ethnic and demographic biases to elicit more objective and stable results — with zero administrative burden on clinicians and parents. With a team comprising machine learning experts, pediatric clinicians and developmental experts with extensive history of research and service in the field, the ACoR score can significantly improve outcomes by either boosting sensitivity of current screening or slashing false positives by half.

Thus, the principal aims this study are the following:

- **Aim 1: Reduce false positives in current screening protocols.** The current high false positive rate exacerbates post screen wait-time, which is often the main source of diagnostic delay. To evaluate the *hypothesis: ACoR can cut down upto 50% of false positives*, we plan to track the number of cases in which MCHAT-F triggers a flag, but our tool does not. Our goal here is to evaluate the positive predictive value (PPV) of ACoR, under high specificity conditions (> 95%).
- **Aim 2. Evaluate the statistical relationship between the ACoR score and M/CHAT-F, and formalize a joint or conditional operational protocol.** We will characterize statistical association, if any, between the test scores. *Hypothesis: The uncertainties or errors in the two tests are are statistically independent*. Additionally, we will evaluate our ability to boost performance by conditioning the sensitivity-specificity trade-offs on the M-CHAT/F score of individual patients.
- **Aim 3. Evaluate the effectiveness of ACoR in a demographically diverse population with a range of socio-economic confounders.** *Hypothesis: A questionnaire-free approach has the potential to mitigate biases that arise from limitation of language, cultural barriers, and demographic diversity, e.g. disproportionately failing to diagnose children with average to above-average intelligence in diverse populations,<sup>[10]</sup> and under-reporting of symptoms by parents or primary care-givers due to cultural differences.<sup>[11]</sup>*
- **Aim 4. Characterize heterogeneity of ASD presentation by relating it to patterns in medical history, and predictive co-morbidities.** Heterogeneous presentation is a key barrier in the mechanistic understanding of ASD pathobiology. *Hypothesis: We can characterize the distinct classes and/or hierarchies of co-morbidities, by leveraging our ability to disambiguate them from individual medical histories*. This will shed light into the potentially intrinsic classes of the underlying disease processes, and refine/inform intervention design.

Thus, we are proposing to exploit observed co-morbidities in children who ultimately meet the criteria for ASD to develop a risk estimation pipeline, and predict future clinical diagnosis under 2 years of age. Orthogonal to checklists, we aim to reduce the median diagnostic age for ASD, by reducing the long post-screen wait times,<sup>[5]</sup> by significant boosts in positive predictive value, reduction in false positives, and increased sensitivities at little or no loss of specificity, and at no additional administrative burden or resource utilization.

### 3. RESEARCH STRATEGY

**3.1. Significance:** Autism spectrum disorder is a developmental disability associated with significant social, communication, and behavioral challenges. The prevalence of ASD has risen dramatically in the United States from 1 in 10,000 in 1972 to 1 in 59 children in 2014, with males diagnosed at nearly four times the rate of females.<sup>[12], [13]</sup> There is a current lack of consensus on whether increased awareness and recent changes in diagnostic practices<sup>[1]</sup> can fully explain this trend.<sup>[14]</sup> Nevertheless, with possibly over 1% of individuals affected worldwide,<sup>[15]</sup> ASD is a human condition with potentially serious negative impacts on individuals, families, and communities. Early detection can and does improve outcomes,<sup>[1]</sup> and is of paramount importance when designing interventions, and is aligned with the envisioned goal of this initiative, as supported by the National Advisory Mental Health Council (NAMHC) (<https://www.nimh.nih.gov/funding/grant-writing-and-application-process/concept-clearances/2018/early-screening-for-autism-spectrum.shtml>).

Even though ASD may be reliably diagnosed as early as the age of two,<sup>[13]</sup> children frequently remain undiagnosed until after the fourth birthday.<sup>[16]</sup> At this time, there are no laboratory tests for ASD, so a careful review of behavioral history and social interactions is necessary for a clinical diagnosis.<sup>[1], [17]</sup> Starting with being flagged by an initial screen based on standardized checklists presented to parents at the ages between 1.5 and 2 years, a confirmed ASD diagnosis is a multi-step process that very often spans 3 months to 1 year. Most of this time is spent waiting to see qualified providers who can carry out the evaluation necessary for a clinical diagnosis. This extended wait is stressful to families, and impacts patient outcomes by delaying entry into time-critical intervention programs. While lengthy evaluations,<sup>[2]</sup> cost of care,<sup>[3]</sup> lack of providers,<sup>[4]</sup> and lack of comfort in diagnosing ASD by primary care providers<sup>[4]</sup> are all responsible to varying degrees,<sup>[18]</sup> one obvious factor responsible is the number of false positives produced in the initial ASD-specific screening tools in use today. For example, the M-CHAT/F, the most widely used screen,<sup>[1], [6]</sup> produces about over 85 false positives out of every 100 people flagged for further diagnostic evaluation, contributing to extended queues.<sup>[18]</sup> The impact from an excessive number of false positives is exacerbated by the current limited access to care and sparse availability of resources except near urban academic centers.<sup>[18], [19]</sup>

The standardized questionnaires attempt to measure risk by direct observation of behavioral symptoms, as reported by untrained observers (parents). Hence the current screening tests are only as good as the ability of the questions to discern and disambiguate behavior in infants and toddlers on casual observation, and on the ability of parents and caregivers to correctly interpret and answer the items without bias. This has lead to possibility of under-diagnosis in diverse communities as reflected by the lower apparent prevalence among African-American and Hispanic children. Also, children with average or higher-than-average cognitive abilities seem to have been under-diagnosed as reported in large scale population studies.<sup>[1]</sup> Borderline cases are typically problematic to screen for due to the possibility of subjective interpretation that is built into questionnaire based risk assessment. Responses to checklists are clearly confounded by a host of socio-economic (SES) variables, potential interpretive biases, and cultural differences. The heterogeneity of presentation also causes issues, since a potential plurality of symptom classes makes it harder for clinicians to recognize borderline cases, or on-the-fly combine observed co-morbidities with scores from standardized screening tools.

In this study, we operationalize a documented aspect of ASD symptomology in that it has a wide range of co-morbidities occurring at much higher rates than in the general population.<sup>[1]</sup> The ACoR methodology we propose in this grant can address the aforementioned complicated challenges of ASD screening, by distilling incipient predictive patterns of elevated risk from past medical history of individual patients, gleaned by machine learning algorithms from large de-identified databases of retrospective patient records. Powered by novel stochastic learning algorithms, we reverse-engineer sparse noisy uncertain diagnostic code sequences into actionable signatures; in effect giving us a fundamentally new approach to ASD screening and risk evaluation.

**Potential Impact of ACoR In Science and Health:** An automated diagnostic or screening capability that might be administered with little or no specialized training, requires no behavioral observations, and is functionally independent of the current tools has the potential for immediate transformative impact on patient care.

That such predictions of neuropsychiatric disorders might be possible from analyzing patterns in individual medical histories is suggested by the fact that parents of children with ASD often notice a diagnosable developmental problem before their child's first birthday; while vision and hearing problems are not uncommon in the first year, differences in social, communication, and fine motor skills have been reported to be evident from about 6 months of age.<sup>[20]-[22]</sup>

**Parallel Screening in Pediatric Primary Clinic:** To achieve the specific goals outlined in the specific aims of this study, we will gather data from both the child and the primary caregiver of all patients in the participating UCM primary pediatric primary care clinic, and test the sensitivity and specificity of ACoR against the most commonly used screening tool M-CHAT/F, by an ADOS-2 based (near) gold-standard evaluation of patients flagged by either tool. Using these data and the inferred statistical dependency (or the lack thereof) properties between the screening tools, ACoR can tailor the selection of sensitivity/specificity trade-offs to the particular informant and to the age of the child, with the view to optimizing global characteristics such as maximizing the PPV or the sensitivity of the screening process. Additionally, the ACoR algorithm will identify categories of heterogeneity that will lead to mechanistic insights into ASD pathobiology.

Thus, the ACoR methodology is potentially able to screen instantaneously every child in primary care, for whom past medical history is available, with zero administrative and resource burden. Our results suggest that ACoR has superior predictive performance to existing screening tools, along with a host of other advantages that directly relate to the stated specific aims of this study.

**Significance of Specific Aim 1:** A significant contribution to the current diagnostic delay arises from families waiting in queue for diagnostic evaluations.<sup>[18]</sup> We expect ACoR to be able to cut down the number of false positives significantly, thus reducing the number of children currently flagged for diagnostic evaluation, which potentially cuts down the wait-time, thereby reducing diagnostic delays. Under Specific Aim 1, our goal is to track the fraction of cases where ACoR correctly signals no-risk while MCHAT-F produces a positive flag.

**Significance of Specific Aim 2:** In our preliminary studies, we established that ACoR outperforms M-CHAT/F by considering the average reported performance of M-CHAT/F in a recent study<sup>[23]</sup> on a large cohort with near-universal screening carried out at the Children's Hospital of Philadelphia (CHOP). However, not having observed the ACoR and the M-CHAT/F scores jointly for individual patients, our preliminary studies lack objective assessment of statistical dependence between the two scores. While the very nature of the methodologies suggest functional independence, specific Aim 2 will investigate and establish this rigorously.

Functional independence from existing tools implies we can combine the scores; especially leveraging the population stratification induced by the M-CHAT/F scores as reported by the CHOP study to significantly boost combined screening performance. In particular, since patients in the lower M-CHAT/F score bracket have a smaller chance of an ASD diagnosis compared to the high risk upper brackets, we can tailor the sensitivity/specificity trade-offs in the ACoR to maximize either the global PPV or the global sensitivity without losing specificity. Our preliminary results suggest that the expected gains are substantial, with the possibility of doubling the PPV, or increasing the sensitivity by over 50% while keeping the specificity above 95%. Specific aim 2 will investigate the viability of the preliminary results in a pediatric primary care setting.

**Significance of Specific Aim 3:** While still lacking the certainty of a diagnostic blood test, use of subtle patterns emergent in the diagnostic history to estimate risk might help reduce the subjective component in questionnaire-based screening tools, resulting in reduced effect of potential language and cultural barriers in diverse populations.<sup>[1]</sup> With a significant portion of the cohort expected to be African Americans and Hispanics in our primary care clinic, our comparative investigations will be able to explicitly answer these questions.

**Significance of Specific Aim 4:** Despite unprecedented advances in charting the numerous genetic variations,<sup>[24]</sup> and established to be highly heritable,<sup>[25]</sup> the etiology of autism is still unclear.<sup>[26], [27]</sup> Despite tremendous recent progress, efforts to identify causal biomarkers for ASD have had limited success. Currently, over one hundred genes have been shown to contribute to autism risk,<sup>[24], [28], [29]</sup> and it is estimated that up to 1000 genes might be involved in ASD pathogenesis.<sup>[30]</sup> Still, genetic interactions and mechanisms have accounted for a limited number of ASD cases,<sup>[31]</sup> potentially implicating environmental triggers that work alongside genetic predispositions. The plausible sources of risk are estimated to range from prenatal factors such as maternal infection and inflammation, diet, and household chemical exposures, to autoimmune conditions and localized inflammation of the central nervous system after birth.<sup>[26], [27], [32]–[37]</sup> The heterogeneity of ASD presentation admits the possibility of a plurality of etiologies with converging pathophysiological pathways, making the investigation of the etiology of future risk modulation extremely challenging. Specific Aim 4 will aim to unravel clues to mechanistic drivers by charting and categorizing the heterogeneous presentation by the nature of past diagnostic pattern in individual medical histories.

In our preliminary investigations standard machine learning tools failed to achieve clinically meaningful performance; the available data is too sparse for off-the-shelf deep learning frameworks<sup>[38]</sup> to make personalized

predictions, and standalone classifiers or regressors fail to exploit the temporal dynamics embedded in the sparse diagnostic histories, requiring us to devise novel machine inference algorithms and feature engineering approaches to distill effective risk predictors. Compared to attempts at identifying biomarkers from differential expression of genes,<sup>[39]–[42]</sup> implicated in neuroinflammation and other comorbid disorders, our predictive performance in preliminary studies is substantially better, with no extra tests that require drawing blood, and is validated on positive cohort sizes at least two orders of magnitude, and control cohorts over three orders of magnitude larger.

### 3.2. Innovation:

**Paradigm Shift in ASD Screening:** Despite extensive documentation of co-morbidities, a risk estimator that makes reliable predictions for individuals — based purely on co-morbidity patterns — has never been reported to the best of our knowledge. The sparsity of available diagnostic codes corresponding to individual subjects, and the general absence of physiological disorders that would uniquely signal the eventual emergence of symptoms indicative of a clinical ASD diagnosis, combined with the heterogeneity of ASD presentation, make such an endeavor challenging. In this study we leverage our preliminary work on the formulation of a *first-of-its-kind* framework to make predictions based on models of statistically curated patterns of diagnostic code sequences automatically learned from sufficiently large databases of electronic health records (EHR), that achieves an out-of-sample AUC exceeding 80% for either gender from just over 2 years of age. The machine learning tools that make this possible are also fundamentally novel, designed to address the specific issues in handling sparse, noisy categorical diagnostic sequences.


**3.3. Approach:** The technical approach of this study consists of the development and extension of the ACoR methodology from our preliminary studies, and application in a primary care setting with view to carrying out objective comparisons between M-CHAT/F and ACoR. Furthermore, we plan to assess our ability to boost performance from a conditional combination of the two scores.

**Preliminary Studies:** We describe the formulation of the ACoR score, and the underlying principles that distill the estimated risk from EHR databases.

**Source of Electronic Patient Records in Preliminary Studies:** Of the two independent sources of clinical incidence data used in our preliminary study, the primary source used to train our predictive pipeline is the Truven Health Analytics MarketScan® Commercial Claims and Encounters Database for the years 2003 to 2012<sup>[43]</sup> (referred to as the Truven dataset). For our analysis, we extracted histories of patients within the age of 0 – 9 years, and excluded patients who do not satisfy the following criteria: 1) At least one code of any available phenotypes is present, 2) Lag between first and last available record for a patient should be at least 15 weeks. These exclusion criteria ensure that we are not considering patients who have too few observations to either train on, or predict outcomes from. For training, we analyzed over 4M children ( $n = 4.4M$ ), with 30M diagnostic records (16,649,548 for males and 14,318,303 for females with 9,835 unique diagnostic codes).

While the Truven database is used for both training and out-of-sample cross-validation with held-back patient data, our second independent dataset (referred to as the UCM dataset) consisting of de-identified diagnostic records for children treated at the University of Chicago Medical Center between the years of 2006 to 2018, aids in further cross-validation. We considered children between the ages of 0 – 5 years, and applied the same exclusion criteria as the Truven dataset.

**Time-series Modeling of Diagnostic History:** Individual diagnostic histories can have long-term memory,<sup>[44]</sup> implying that the order, frequency, and comorbid interactions between diseases are potentially important for assessing the future risk of our target phenotype. Our approach to analyzing patient-specific diagnostic code sequences consists of representing the medical history of each patient as a set of stochastic categorical time-series — one each for a specific group of related disorders — followed by the inference of stochastic generators for these individual data streams. These inferred generators are from a special class of Hidden Markov Models (HMMs), referred to as Probabilistic Finite State Automata (PFSA).<sup>[45]</sup> The inference algorithm we use is distinct from classical HMM learning, and has important advantages related to the ability to infer structure, and sample complexity. We infer a separate class of models for the positive and control cohorts, and then the problem reduces to determining the probability that the short diagnostic history from a new patient arises from the positive as opposed to the control category of the inferred models. Importantly, the individual histories are typically short, often have large randomly varying gaps, and we have no guarantee that model-structural assumptions<sup>[46], [47]</sup> (linearity, additive noise structure, etc.) often used in the standard




**Fig. 1.** Predictive Performance. Panel A shows the ROC curves for males and females. Panel B shows the feature importance inferred by our prediction pipeline. The most important feature is related to immunologic disorders, and we note that in addition to features related to individual disease categories, we also have the mean control likelihood (rank 3), which may be interpreted as the average likelihood of the diagnostic patterns corresponding to the control category as opposed to the positive category. Panels C and D show the spatial variation in the achieved predictive performance at 150 weeks, measured by AUC, for males and females, respectively. Gray areas lack data on either positive or negative cases. These county-specific AUC plots show that the performance of the algorithm has relatively weak geospatial dependence, which is important in the light of current uneven distribution of diagnostic resources.

time-series analysis is applicable here. Also, the categorical observations are drawn from a large alphabet of possible diagnostic codes, which degrades statistical power.

**Step 1: Partitioning The Human Disease Spectrum:** To address these issues, we begin by partitioning the human disease spectrum into 17 non-overlapping categories, which remain fixed throughout the analysis. Each category is defined by a set of diagnostic codes from the International Classification of Diseases, Ninth Revision (ICD9). For this study, we considered 9,835 distinct ICD9 codes (and their ICD10 General Equivalence Mappings (GEMS)<sup>[48]</sup> equivalents). We came across 6,089 distinct ICD-9 codes and 11,522 distinct ICD-10 codes in total in the two datasets we analyzed. Transforming the diagnostic histories to report only the broad categories reduces the number of distinct codes that the pipeline needs to handle, thus improving statistical power. The trade-offs for this increased power consist of 1) the loss of distinction between disorders in the same category, and 2) some inherent subjectivity in determining the constituent ICD9 codes that define each category, *e.g.* an ear infection may be classified either an otic disease or an infectious one.

We do not pre-select the phenotypes; we want our algorithm to seek out the important patterns without any manual curation of the input data. The limitation of the set of phenotypes to 9835 unique codes arises from



**Fig. 2.** More details on Predictive Performance and Variation of Inferred Risk. Panel A illustrates AUC achieved as a function of patient age, for the Truven and UCM datasets. The shaded area outlines the 2 - 2.5 years of age, and shows that we achieve > 80% AUC for either gender from shortly after 2 years. Panel B illustrates how the average risk changes with time for the control and the positive cohorts. Panel C shows the distribution of the prediction horizon: the time to a clinical diagnosis after inferred relative risk crosses 90%. Panel d illustrates the risk progression of a specific, ultimately autistic male child in the Truven database. Abbreviations in the legend: ill defn. (Symptoms, Signs, And Ill-Defined Conditions), musc. skltl. (Diseases Of The Musculoskeletal System And Connective Tissue), cond. orig. in perintl. (Certain Conditions Originating In The Perinatal Period), immun. (Endocrine, Nutritional And Metabolic Diseases, And Immunity Disorders), nerv. & sensory (Diseases Of The Nervous System And Sense Organs), respir. (Respiratory Disorders), and digest. (Digestive Disorders).

excluding patients from the database who have very few and rare codes that will skew the statistical estimates. Next, we process raw diagnostic histories to generate data streams that report only the categories instead of the exact codes. For each patient, his or her past medical history is a sequence  $(t_1, x_1), \dots, (t_m, x_m)$ , where  $t_i$  are timestamps and  $x_i$  are ICD9 codes diagnosed at time  $t_i$ . We map individual patient history to a three-alphabet time series  $z^k$  corresponding to the disease category  $k$ , as follows. For each week  $i$ ,


$$z_i^k = \begin{cases} 0 & \text{if no diagnosis codes in week } i \\ 1 & \text{if there exists a diagnosis of category } k \text{ in week } i \\ 2 & \text{otherwise} \end{cases} \quad (1)$$

The time-series  $z^k$  is terminated at a particular week if the patient is diagnosed with ASD the week after. In summary, each patient is now represented by 17 mapped trinary series, which we use next to infer population-level PFSA models.


**Step 2: Model Inference & The Sequence Likelihood Defect:** The mapped series, stratified by gender, disease-category, and ASD diagnosis-status are considered to be independent realizations or sample paths from relatively invariant stochastic dynamical systems; and we explicitly model these systems as HMMs. We model the positive and the control cohorts for each gender, and in each disease category separately, ending up with a total of 68 HMMs at the population level (17 categories, 2 genders, 2 cohort-types: positive and control). Each of these inferred models is a PFSA; a directed graph with probability-weighted edges, and acts as an optimal generator of the stochastic process driving the sequential appearance of the three letters (as defined by Eq. (1)) corresponding to each gender, disease category, and cohort-type. The modeling objective here is to exploit the relative differences in these probabilistic models to reliably infer the cohort-type of a new patient from their individual sequence of past diagnostic codes. To that effect, we generalized the well-known notion of Kullbeck-Leibler (KL) divergence<sup>[49], [50]</sup> between probability distributions to a divergence  $\mathcal{D}_{\text{KL}}(G||H)$  between ergodic stationary categorical stochastic processes<sup>[51]</sup>  $G, H$  as:

$$\mathcal{D}_{\text{KL}}(G||H) = \lim_{n \rightarrow \infty} \frac{1}{n} \sum_{x:|x|=n} p_G(x) \log \frac{p_G(x)}{p_H(x)} \quad (2)$$


### A. Standalone PPV vs Sensitivity or Precision Recall Curves



### B. M-CHAT/F Conditioned PPV vs Sensitivity (Prevalence range 1.7% to 2.3%)



### C. Reduced # of Flags vs Boosted Sensitivity Relative To Standalone M-CHAT/F



**Fig. 3. Metrics relevant to clinical practice: PPV vs Sensitivity trade-offs.** Panel A shows the precision/recall curves, i.e., the trade-off between PPV and sensitivity. Panel B shows how we can boost performance using population stratification from the distribution of M-CHAT/F scores in the population, as reported by the CHOP study.<sup>[23]</sup> Panel C illustrates the boosted performance compared to M-CHAT/F alone, measured by the relative percentage increase in sensitivity, and percentage decrease in positive screens. Note that the population prevalence impacts this optimization, and hence we have a distinct curve for each prevalence value (1.7% is the CDC estimate, while 2.23% is reported by the CHOP study). The two extreme operating zones marked as High Precision (HP) and High Recall (HR): if we choose to operate in HR, then we do not reduce the number of positive screens by much, but maximize sensitivity, while by operating in HP, we do not increase sensitivity by much but double the PPV achieved in current practice. Note in all these zones we maintain specificity above 95%, which is the current state of art, implying that by doubling the PPV, we can halve the number of positive screens currently reported, thus potentially sharply reducing the queues and wait-times.

where  $|x|$  is the sequence length, and  $p_G(x), p_H(x)$  are the probabilities of sequence  $x$  being generated by the processes  $G, H$  respectively. Defining the log-likelihood of  $x$  being generated by a process  $G$  as :

$$L(x, G) = -\frac{1}{|x|} \log p_G(x) \quad (3)$$

The cohort-type for an observed sequence  $x$  — which is actually generated by the hidden process  $G$  — can be formally inferred from observations based on the following provable relationships:

$$\lim_{|x| \rightarrow \infty} L(x, G) = \mathcal{H}(G) \quad (4a)$$

$$\lim_{|x| \rightarrow \infty} L(x, H) = \mathcal{H}(G) + D_{KL}(G||H) \quad (4b)$$

where  $\mathcal{H}(\cdot)$  is the entropy rate of a process.<sup>[49]</sup> Importantly, Eq. (4) shows that the computed likelihood has an additional non-negative contribution from the divergence term, when we choose the incorrect generative process. Thus, if a patient is eventually going to be diagnosed with ASD, then we expect that the disease-

TABLE 1  
Standalone ACoR PPV Achieved

(For Comparison M-CHAT/F Performance: sensitivity=38.8%, specificity=95%, PPV=14.6% between within 26 months ( $\approx 112$  weeks))

| weeks | specificity | sensitivity | PPV  | gender | dataset |
|-------|-------------|-------------|------|--------|---------|
| 100   | 0.92        | 0.39        | 0.14 | F      | UCM     |
| 100   | 0.95        | 0.39        | 0.19 | M      | UCM     |
| 100   | 0.93        | 0.39        | 0.13 | F      | Truven  |
| 100   | 0.91        | 0.39        | 0.10 | M      | Truven  |
| 112   | 0.93        | 0.39        | 0.16 | F      | UCM     |
| 112   | 0.95        | 0.39        | 0.20 | M      | UCM     |
| 112   | 0.96        | 0.39        | 0.22 | F      | Truven  |
| 112   | 0.95        | 0.39        | 0.17 | M      | Truven  |
| 150   | 0.94        | 0.39        | 0.19 | F      | UCM     |
| 150   | 0.98        | 0.39        | 0.34 | F      | Truven  |
| 150   | 0.97        | 0.39        | 0.26 | M      | Truven  |
| 150   | 0.97        | 0.39        | 0.26 | M      | UCM     |

specific mapped series corresponding to her diagnostic history be modeled by the PFSA in the positive cohort. Denoting the PFSA corresponding to disease category  $j$  for positive and control cohorts as  $G_+^j, G_0^j$  respectively, we can compute the *sequence likelihood defect* (SLD,  $\Delta^j$ ) as:

$$\Delta^j \triangleq L(G_0^j, x) - L(G_+^j, x) \rightarrow D_{KL}(G_0^j || G_+^j) \quad (5)$$

With the inferred population-level PFSA models and the individual diagnostic history, we can now estimate the SLD measure on the right-hand side of Eqn. (5). The higher this likelihood defect, the higher the similarity of the patient's history to ones that have an eventual ASD diagnosis with respect to the disease category being considered. SLD is the core novel analytic tool used in this study to tease out information relevant to the risk estimator and is key to the design of our risk estimation pipeline.

**Step 3: Risk Estimation Pipeline With Semi-supervised & Supervised Learning Modules:** Ultimately, the risk estimation pipeline operates on patient specific information limited to the gender and available diagnostic history from birth, and produces an estimate of the relative risk of ASD diagnosis at a specific age, with an associated confidence value. To learn the parameters and associated model structures of this pipeline, we transform the patient specific data to a set of engineered features, and the feature vectors realized on the positive and control sets are then used to train a gradient-boosting classifier.<sup>[52]</sup> Of the set of engineered features, the most important are the disease-category-specific SLD described above. For example, if  $SLD > 0$  for a specific patient for every disease category, then he or she is likely to have an ASD diagnosis eventually. However, not all disease categories are equally important for this decision; parametric tuning of the classifier allows us to infer the optimal combination weights, as well as compute the relative risk with associated confidence. In addition to category-specific SLDs, we use a range of other derived quantities as features, including the mean and variance of the defects computed over all disease categories, the occurrence frequency of the different disease groups, etc. The top 15 features used in our pipeline may be ranked in order of their relative importance (See Fig. 1B), by estimating the loss in performance when dropped out of the analysis, and the importance of infections and immunologic disorders are clearly evident (See Fig. 1B).

**Calculating Relative Risk:** Our pipeline maps medical histories to a score, which is interpreted as a raw indicator of risk — higher this value, higher the probability of a future diagnosis. However, to make crisp predictions, we must choose a decision threshold for this raw score. Conceptually identical to the notion of Type 1 and Type 2 errors in classical statistical analyses, the choice of a threshold trades off false positives (Type 1 error) for false negatives (Type 2 error): choosing a small threshold results in predicting a larger fraction of future diagnoses correctly, *i.e.* have a high true positive rate (TPR), while simultaneously suffering from a higher false positive rate (FPR), and vice versa. We choose thresholds for the standalone ACoR method by maximizing the  $F_1$ -score, defined as the harmonic mean of sensitivity and specificity, to make a balanced trade-off between the two kinds of errors. The *relative risk* is then defined as the ratio of the raw pipeline score to the chosen decision threshold. While the raw score does not give us actionable information, the relative risk being close to or greater than 1.0 for a specific child signals the need for intervention.

**Standalone Predictive Performance:** The standalone performance of our risk estimator is summarized in Fig. 1 and Fig. 2. The task of predicting if a patient has a future ASD diagnosis, at an earlier date compared to the clinical diagnosis, may be viewed as a binary classification problem. In our case, we achieve an out-of-sample AUC of 82.3% for males and 82.5% for females at 125 weeks of age for the Truven dataset. In the UCM dataset, our performance is comparable: 83.1% and 81.3% for males and females respectively at 125 weeks of age. The good agreement of the out-of-sample performance on these independent datasets lends strong evidence for the claims made in this study. The specificity, sensitivity, PPV trade-offs are shown in Table 1.

We enumerate the top 15 predictive features in Fig. 1B. We also computed the county-specific performance of the risk pipeline for the Truven dataset, and we got nearly uniform performance across the country for both genders, with the exception of few isolated counties lacking patients in the appropriate age groups (See Fig. 1, panels C and D) which prevented us from estimating AUC for those counties. Thus the performance of the algorithm is relatively agnostic to the number of local diagnoses, which is import in light of the fact that crucial diagnostic resources currently have a very uneven distribution (only 7% of developmental pediatricians practice in rural areas, and some states in US do not even have a developmental pediatrician<sup>[18], [19]</sup>).

Fig. 2A illustrates the variation of the AUC with increasing age of the subjects plotted with 99% confidence bounds: the increase is very nearly linear, with a change of gradient near the 150 week mark. We suspect that the median diagnosis age in the databases ( $\approx$  150 weeks) manifests this inflection. The curves for the smaller UCM dataset are less smooth, probably due to more uncertainty. We find that while the AUC gradients are different in the two datasets, they tend to match up in later ages. The differences in the early ages are possibly due to differences in patient statistics: a larger number of patients in Truven at the earlier ages with a relatively smaller number of observations on average.

We plot the absolute or raw risk over time for males and females for the out-of-sample control and positive cohorts in Fig. 2B. We see that while the risk for the control cohort remains more or less stable, that for the positive cohort rapidly increases. Notably, in these risk plots, averaged over the population, we see disambiguation early, right from 50 weeks. Also, we see a saturation of the risk after 150 weeks, which corresponds to the median diagnosis age in the database (approx. 150 weeks). Thus, if a child is not diagnosed up to that age, then the risk falls, since the probability of a diagnosis in the population starts to go down after this age.

**Calculating PPV, Sensitivity & Specificity Trade-offs & M-CHAT/F Comparison:** The sensitivity vs PPV plots, also known as the precision-recall curves (See Fig. 3A) are constructed in a similar fashion as the ROC curves by varying the decision threshold. These curves allow direct comparison with the state of the art screening tests, e.g., M-CHAT/F, in a manner that is most relevant to clinical practitioners. Guthrie *et al.*<sup>[23]</sup> from Children's Hospital of Philadelphia (CHOP) has recently demonstrated that when applied as a nearly universal screening tool, M-CHAT/F has a sensitivity of 38.8%, specificity of 94.9% and PPV of 14.6%, implying that out of every 100 children who in fact ave ASD, the M-CHAT/F flags about 39, and out of every 100 children it flags, about 85 are false positives. The PPV is affected by the prevalence of the disease. This work is the only large-scale study of M-CHAT/F ( $n=20,375$ ) we are aware of with sufficient follow-up after the age of four years to provide a reasonable degree of confidence in the reported performance values.

Comparing the performance metrics achieved at different age groups across data sets and genders for our pipeline (See Table 1), we conclude that our approach produces a strictly superior PPV (exceeding M-CHAT/F PPV by at 14% (14.1-33.6%) when sensitivity and specificity are held at comparable values around the age of 26 months ( $\approx$  112 weeks). We cannot compare at other operating points due to a lack of M-CHAT/F performance characterization anywhere else.

**Boosting Performance Via Leveraging Population Stratification Induced By M-CHAT/F:** In this study, we leverage the population stratification induced by an existing independent screening test (M-CHAT/F) to improve combined performance. Here a combination refers to the conditional choice of the sensitivity/specificity trade-offs for our tool in each sub-population such that the overall performance is optimized with respect to whether we wish to maximize the PPV or the sensitivity at a specified minimum level of specificity. Assume that there are  $m$  sub-populations such that: the sensitivities, specificities achieved, and the prevalences in each sub-population are given by  $s_i, c_i$  and  $\rho_i$  respectively, with  $i \in \{1, \dots, m\}$ . Let  $\beta_i$  be the relative size of each

TABLE 2

Population Stratification Results on large M-CHAT/F Study(n=20,375) reproduced from Guthrie *et al.*<sup>[23]</sup>

| Id      | Sub-population        | Test Result          | ASD pos. | ASD Neg. | Total % |
|---------|-----------------------|----------------------|----------|----------|---------|
| A       | M-CHAT/F $\geq 8$     | Positive             | 0.34%    | 0.64%    | 0.99%   |
| B       | M-CHAT/F $\in [3, 7]$ | Positive (follow-up) | 0.52%    | 4.39%    | 4.91%   |
| C       | M-CHAT/F $\in [3, 7]$ | Negative (follow-up) | 0.14%    | 3.1%     | 3.24%   |
| D       | M-CHAT/F $\in [0, 2]$ | Negative             | 1.22%    | 89.63%   | 90.86%  |
| Total % |                       |                      | 2.23%    | 97.77%   | 100%    |

TABLE 3

Boosted Sensitivity, specificity and PPV Achieved at 26 months Personalized Operation Conditioned on M-CHAT/F Scores

| M-CHAT/F Outcome    |         |         |              | global performance (Truven) |              |       | global performance (UCM) |              |       | prevalence* |
|---------------------|---------|---------|--------------|-----------------------------|--------------|-------|--------------------------|--------------|-------|-------------|
| 0-2 NEG             | 3-7 NEG | 3-7 POS | $\geq 8$ POS | speci-ficity                | sensi-tivity | PPV   | speci-ficity             | sensi-tivity | PPV   |             |
| specificity choices |         |         |              |                             |              |       |                          |              |       |             |
| 0.2                 | 0.54    | 0.83    | 0.98         | 0.95                        | 0.585        | 0.209 | 0.95                     | 0.505        | 0.186 | 0.022       |
| 0.21                | 0.53    | 0.83    | 0.98         | 0.95                        | 0.586        | 0.208 | 0.95                     | 0.506        | 0.184 | 0.022       |
| 0.42                | 0.87    | 0.98    | 0.99         | 0.98                        | 0.433        | 0.331 | 0.98                     | 0.347        | 0.284 | 0.022       |
| 0.48                | 0.87    | 0.97    | 0.99         | 0.98                        | 0.432        | 0.331 | 0.98                     | 0.355        | 0.289 | 0.022       |
| 0.38                | 0.54    | 0.94    | 0.98         | 0.95                        | 0.736        | 0.203 | 0.95                     | 0.628        | 0.178 | 0.017       |
| 0.3                 | 0.55    | 0.94    | 0.98         | 0.95                        | 0.737        | 0.203 | 0.95                     | 0.633        | 0.179 | 0.017       |
| 0.58                | 0.96    | 0.98    | 0.99         | 0.98                        | 0.492        | 0.302 | 0.98                     | 0.373        | 0.247 | 0.017       |
| 0.59                | 0.96    | 0.98    | 0.99         | 0.98                        | 0.491        | 0.303 | 0.98                     | 0.372        | 0.248 | 0.017       |
| 0.46                | 0.92    | 0.97    | 0.99         | 0.977                       | 0.534        | 0.291 | 0.977                    | 0.448        | 0.256 | 0.017       |
| 0.48                | 0.92    | 0.97    | 0.99         | 0.978                       | 0.533        | 0.292 | 0.978                    | 0.448        | 0.257 | 0.017       |


\*Prevalence reported by CDC is 1.7%, while the CHOP study reports a value of 2.23%. Results depend on the prevalence estimate.

sub-population. Then, we can show:

$$s = \sum_{i=1}^m s_i \gamma_i, \text{ and } c = \sum_{i=1}^m c_i \gamma'_i \text{ where we have denoted: } \gamma_i = \beta_i \frac{\rho_i}{\rho}, \text{ and } \gamma'_i = \beta_i \frac{1 - \rho_i}{1 - \rho} \quad (6a)$$

and  $s, c, \rho$  are the overall sensitivity, specificity, and prevalence. Knowing the values of  $\gamma_i, \gamma'_i$ , we can carry out an  $m$ -dimensional search to identify the feasible choices of  $s_i, c_i$  pairs for each  $i$ , such that some global constraint is satisfied, e.g. minimum values of specificity, sensitivity, and PPV. We consider 4 sub-populations defined by M-CHAT/F score brackets,<sup>[23]</sup> and if the screen result is considered a positive (high risk, indicating the need for a full diagnostic evaluation) or a negative, i.e., low risk: 1) score  $\leq 2$  screening ASD negative, 2) score  $[3 - 7]$  screening ASD negative on follow-up, 3) score  $[3 - 7]$  and screening ASD positive on follow-up, and 4) score  $\geq 8$ , screening ASD positive. (See Table 2). The “follow-up” in the context of M-CHAT/F refers to the re-evaluation of responses by qualified personnel. We use published data on the relative sizes and the prevalence statistics in these sub-populations<sup>[23]</sup> to compute the feasible conditional choices of our operating point to strictly supersede M-CHAT/F performance. Two limiting operating conditions are of special interest here, where we maximize PPV under some minimum specificity and sensitivity (denoted as the High Precision or the HP operating point), and where we maximize sensitivity under some minimum PPV and specificity (denoted as the High Recall or the HR operating point). Taking these minimum values of specificity, sensitivity, and PPV to be those reported for M-CHAT/F, we identify the set feasible set of conditional choices in a four dimensional decision space that would outperform M-CHAT/F in universal screening.

This ultimately yields an overall performance significantly superior to M-CHAT/F alone. We carry out a four dimensional search at the age of 26 months ( $\approx 112$  weeks) to identify the feasible region with  $PPV > 14.6\%$  and  $sensitivity > 38.8\%$  simultaneously while keeping  $specificity > 94\%$ . These four dimensions reflect the independent choice of sensitivities in the corresponding sub-populations. For each set of choices, the associ-



**Fig. 4.** Difference in occurrence frequencies of diagnostic codes between true positive (TP) and true negative (TN) predictions in males. The color coding shows the disease categories of the co-morbidities.

ated specificities are read-off from our fixed pre-computed ROC curve corresponding to 112 weeks, and then the overall sensitivity, specificity and PPV are calculated using standard relationships.


We get a PPV close to or exceeding 30% at the high precision (HP) operating point across datasets ( $> 33\%$  fro Truven,  $> 28\%$  for UCM), or a sensitivity close to or exceeding 50% for the high recall (HR) operating point ( $> 58\%$  for Truven,  $> 50\%$  for UCM), when we restrict specificities to above 95% (See Table 3).

It is important to compare these results directly with M-CHAT/F performance, as shown in Fig. 3, panels C. In panel C, we show that for any stable population prevalence between 1.7% and 2.23%, the conditional operation can achieve double the PPV relative to M-CHAT/F alone without losing sensitivity at  $> 98\%$  specificity, or increase the sensitivity by  $\sim 50\%$  without sacrificing PPV and not letting the specificity to drop below 94%.

Importantly, designing rules for conditional operation only requires average population characteristics, *i.e.*, an estimate of ASD prevalence in the sub-populations defined by the relevant brackets of M-CHAT/F scores, and the prevalence of these score brackets in the general population. In particular, M-CHAT/F scores of individual patients are unnecessary for designing the rules themselves, or evaluating the overall expected performance in the population, provided the stratification statistics (Table 2) remains invariant. However, in the proposed study, we will be able to compute explicit dependency relationships between M-CHAT/F and ACoR scores.

**Inferred Co-morbidity Patterns & Normalized Prevalence Comparison:** The predictive ability of our pipeline arises from the difference in patterns of co-morbid disorders between the positive and the control cohorts: the diagnostic history of individual patients is not random and hides key signatures to future neuropsychiatric outcomes. As an illustrative example, a single random patient from the Truven database is illustrated in Fig. 2D. Color-coding the diagnoses according to the broad ICD9 disease categories reveals that for this specific individual, infections and immunological disorders are experienced early to a much higher degree compared to other diseases, and diseases of the nervous system and sensory organs, as well as ill-defined symptoms dominate the latter period. This suggests the necessity of a deeper interrogation of the structure of co-morbid patterns, which we carried out in our preliminary investigations, as described next.

While the ASD co-morbidity burden is reported to be high for nearly the entire spectrum of physiological disorders, in our preliminary we find novel association patterns in normalized prevalence — the odds of experiencing a specific disorder, particularly in the early years (age  $< 3$  years), normalized over all unique disorders experienced in the specified time-frame. Additionally, we only focus on the true positives in the positive cohort and the true negatives in the control cohort. This allows us to investigate patterns that correctly disambiguate future ASD status, *i.e.*, strongly favor one outcome over the other at the individual level (as opposed to population-level prevalence rates), as shown in Fig. 4 for males.



**Fig. 5. Patient flow logic.** Consenting families with children between 18 to 30 months are subjected to both M-CHAT/F and ACoR screens, and those with a MCHAT-F flag is scheduled for an ADOS evaluation for ascertaining ASD status. Note that by our calculations, for every 100 children, we expect to 6 MCHAT-F flags, out of which 4 on average will get a negative diagnosis by ADOS.

Additionally, we found in our preliminary studies indications of : 1) *negative associations*: there are diseases that are negatively associated with ASD diagnosis with respect to normalized prevalence, *i.e.*, having those codes over-represented relative to other codes in one's diagnostic history favors ending up in the control cohort, 2) *gendered impact*: there are gender-specific differences in the impact of specific disorders which will be further investigated in this study.

**Effect of Change In Diagnostic Criteria: Inclusion of PDD & Asperger's Syndrome:** The DSM-5 established a single category of ASD to replace the subtypes of autistic disorder, Asperger syndrome, and pervasive developmental disorder not otherwise specified in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR).<sup>[1]</sup> This aligns with our use of diagnostic codes from ICD9 299.X as specification of an ASD diagnosis, and use GEMS mapping to 299.X from ICD10 codes when we encounter them. Importantly, we found that it is difficult to design a high performing pipeline that recognizes these ASD sub-types separately, even if we so wanted.

**Disambiguation From Unrelated Psychiatric Phenotypes:** We will investigate discrimination between ASD and unrelated psychiatric phenotypes. In our preliminary studies, we investigated this by restricting the control cohort in validation to patients with at least one non-ASD psychiatric code, and obtained high discrimination reaching AUCs over 90% at 100 – 125 weeks of age, suggesting that our pipeline is mostly specific to ASD.

**Sanity Checks: Uncertainty in EHR Records & Baseline Approaches in Machine Learning:** Recent changes in diagnostic practice, *e.g.* increased diagnoses from individual clinicians versus prior eras that only allowed diagnosis from the gold-standard multi-disciplinary teams can increase observed prevalence, and raises the possibility that some diagnostic codes pertaining to ASD in medical history databases could be arising from less restrictive workflows, and are susceptible to increased uncertainty. In our study, we verified that restricting the positive cohort to children with at least two distinct ASD diagnostic codes in their medical histories instead of one, has little impact on out-of-sample predictive performance.

We verified that class imbalance is not inappropriately enhancing our performance, by replacing the control cohort with a random sample of size equal to that of the positive cohort in out-of-sample tests.

We also found that the density of diagnostic codes in a child's medical history by itself is somewhat predictive of a future ASD diagnosis, but not at clinically significant levels.

**Research Design:** ACoR methodology can screen instantaneously every child in primary care, for whom past medical history is available, with zero administrative and resource burden. To achieve the specific goals outlined in the specific aims of this study, we will gather data from both the child and the primary caregiver of all patients in the participating UCM primary pediatric primary care clinic, and test the sensitivity and specificity of

ACoR against the most commonly used screening tool M-CHAT/F, by an ADOS-2 based (near) gold-standard evaluation of patients. Using these data and the inferred statistical dependency (or the lack thereof) properties between the screening tools, ACoR can tailor the selection of sensitivity/specificity trade-offs to the particular informant and to the age of the child, with the view to optimizing global characteristics such as maximizing the PPV or the sensitivity of the screening process. Additionally, the ACoR algorithm will identify categories of heterogeneity that can lead to mechanistic insights into ASD pathobiology.

The key steps in this project are as follows (See Fig. 5):

- 1. Pediatric clinic team will administer M-CHAT/F to incoming children with 16-30 months.
- 2. The University of Chicago Research Informatics Support team will work with the PI and his team to compute the ACoR score corresponding to individual consenting patients
- 3. On being flagged by M-CHAT/F as high risk, or if the ACoR score indicates high risk and teh M-CHAT/F is borderline, the patients will be scheduled for ADOS-2 evaluation overseen by Dr. Smith and his team
- 4. The evaluation scores will be analyzed by the PI and his team to address the specific aims.

The limited scope of this project implies that we need to be aware of the number of ADOS-2 referrals generated due to ACoR, particularly since ADOS-2 evaluations involve significant resource and cost.

**Cohort Selection:** Participants will be approximately 5000 children per year (producing approximately 300 ADOS-2 referrals) who will be evaluated via both the MCHAT-F screening during wellness visits at the 1 year, 1.5 year and 2 year mark, via the standard questionnaire completed by their primary caregivers, and the ACoR algorithm applied to their diagnostic history on file. Inclusion criteria: 1) Child is between 16 and 30 months, 2) Child has diagnostic history on record with at least 5 diagnostic codes, and the first code is at least from 15 weeks in the past. Exclusion criteria: Diagnostic history only consists of health service contact codes.

**3.4. Study Interventions and Measures:** No intervention is planned within this study. Main outcomes are efficacy and applicability of ACoR compared to MCHAT-F.

**Risk To Patients:** The design of the study guarantees that patients suffer no negative impact from the added ACoR screen. Indeed, pursuant to available resources, patients who are flagged will be expedited for ADOS evaluation which eliminates or reduces their wait-times. For some borderline cases, which would have been missed by M-CHAT/F, might get flagged by ACoR, and be scheduled for ADOS, which they would not have had to do with just M-CHAT/F. But this is a positive outcome. Only when the M-CHAT/F is borderline, and the ACoR signifies a high risk, may a patient be scheduled for ADOS-2 who otherwise will not have the referral. Thus there is a small possibility that ACoR might have some false positives that are different from that of M-CHAT/F and hence schedule some children for ADOS, who do not have autism, and might cause some stress in parents and families if they are . The potential societal benefit gained in lieu of this discomfort is the validation of the expected performance boost for ASD screening at the population level PPV by up to 100%, or the sensitivity by 50%.

**Procedures:** Eligible patients at the Department of Pediatrics, University of Chicago (patients who present for a well-child visit or any other non-emergency reason) will be asked for consent for access to their past medical history for carrying out the ACoR screen. If there is a flag either in M-CHAT/F or in ACoR, the attending pediatrician will inform parents of a potential elevated risk of ASD diagnosis, and offer to schedule for an ADOS-2 evaluation. The ADOS-2 evaluation triggered by ACoR flags will be at no cost to the patient.

All study procedures and consent forms will be approved by the University of Chicago Institutional Review Board. For all assessments, basic demographic information, recruitment site, medications and diagnoses assigned by the current clinical treatment team, will be obtained from the parent/caregiver and medical record.

**Data Management:** Data collection forms for demographic and clinical history data, database design and data management procedures will be designed, created and conducted at the University of Chicago under the direction of Dr. Smith. Demographic and clinical history data will be collected and entered into an HIPAA compliant secure database. Data will be entered within one day of collection and will pass through rigorous quality control checks for accuracy and completeness before and after data entry. Monthly reports will be generated to monitor data timeliness, completeness, and accuracy as well as subject flow through the study. Data sets stripped of patient identifiers will be sent electronically to Dr. Chattopadhyay as needed for analysis.

## REFERENCES

- [1] Hyman, S. L., Levy, S. E., Myers, S. M. et al. Identification, evaluation, and management of children with autism spectrum disorder. *Pediatrics* **145** (2020).
- [2] Kalb, L. G. et al. Determinants of appointment absenteeism at an outpatient pediatric autism clinic. *Journal of Developmental & Behavioral Pediatrics* **33**, 685–697 (2012).
- [3] Bisgaier, J., Levinson, D., Cutts, D. B. & Rhodes, K. V. Access to autism evaluation appointments with developmental-behavioral and neurodevelopmental subspecialists. *Archives of pediatrics & adolescent medicine* **165**, 673–674 (2011).
- [4] Fenikilé, T. S., Ellerbeck, K., Filippi, M. K. & Daley, C. M. Barriers to autism screening in family medicine practice: a qualitative study. *Primary health care research & development* **16**, 356–366 (2015).
- [5] Gordon-Lipkin, E., Foster, J. & Peacock, G. Whittling Down the Wait Time: Exploring Models to Minimize the Delay from Initial Concern to Diagnosis and Treatment of Autism Spectrum Disorder. *Pediatr. Clin. North Am.* **63**, 851–859 (2016).
- [6] Robins, D. L. et al. Validation of the modified checklist for autism in toddlers, revised with follow-up (m-chat-r/f). *Pediatrics* **133**, 37–45 (2014).
- [7] Jashar, D. T., Brennan, L. A., Barton, M. L. & Fein, D. Cognitive and adaptive skills in toddlers who meet criteria for autism in dsm-iv but not dsm-5. *Journal of autism and developmental disorders* **46**, 3667–3677 (2016).
- [8] Tye, C., Runicles, A. K., Whitehouse, A. J. O. & Alvares, G. A. Characterizing the Interplay Between Autism Spectrum Disorder and Comorbid Medical Conditions: An Integrative Review. *Front Psychiatry* **9**, 751 (2018).
- [9] Kohane, I. S. et al. The co-morbidity burden of children and young adults with autism spectrum disorders. *PLoS ONE* **7**, e33224 (2012).
- [10] Christensen, D. L. et al. Prevalence and characteristics of autism spectrum disorder among children aged 4 years—early autism and developmental disabilities monitoring network, seven sites, united states, 2010, 2012, and 2014. *MMWR Surveillance Summaries* **68**, 1 (2019).
- [11] Burkett, K., Morris, E., Manning-Courtney, P., Anthony, J. & Shambley-Ebron, D. African american families on autism diagnosis and treatment: The influence of culture. *Journal of Autism and Developmental Disorders* **45**, 3244–3254 (2015).
- [12] Baio, J. et al. Prevalence of Autism Spectrum Disorder Among Children Aged 8 Years - Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2014. *MMWR Surveill Summ* **67**, 1–23 (2018).
- [13] Data & statistics on autism spectrum disorder — cdc (2019). URL <https://www.cdc.gov/nccbdd/autism/data.html>.
- [14] King, M. & Bearman, P. Diagnostic change and the increased prevalence of autism. *Int J Epidemiol* **38**, 1224–1234 (2009).
- [15] Elsabbagh, M. et al. Global prevalence of autism and other pervasive developmental disorders. *Autism Res* **5**, 160–179 (2012).
- [16] Schieve, L. A. et al. Population attributable fractions for three perinatal risk factors for autism spectrum disorders, 2002 and 2008 autism and developmental disabilities monitoring network. *Ann Epidemiol* **24**, 260–266 (2014).
- [17] Volkmar, F. et al. Practice parameter for the assessment and treatment of children and adolescents with autism spectrum disorder. *Journal of the American Academy of Child & Adolescent Psychiatry* **53**, 237–257 (2014).
- [18] Gordon-Lipkin, E., Foster, J. & Peacock, G. Whittling down the wait time: exploring models to minimize the delay from initial concern to diagnosis and treatment of autism spectrum disorder. *Pediatric Clinics* **63**, 851–859 (2016).
- [19] Althouse, L. A. & Stockman, J. A. Pediatric workforce: A look at pediatric nephrology data from the american board of pediatrics. *The Journal of pediatrics* **148**, 575–576 (2006).
- [20] Kozlowski, A. M., Matson, J. L., Horovitz, M., Worley, J. A. & Neal, D. Parents' first concerns of their child's development in toddlers with autism spectrum disorders. *Dev Neurorehabil* **14**, 72–78 (2011).
- [21] Herlihy, L., Knoch, K., Vibert, B. & Fein, D. Parents' first concerns about toddlers with autism spectrum disorder: Effect of sibling status. *Autism* **19**, 20–28 (2015).
- [22] Chawarska, K., Macari, S. & Shic, F. Decreased spontaneous attention to social scenes in 6-month-old infants later diagnosed with autism spectrum disorders. *Biological psychiatry* **74**, 195–203 (2013).
- [23] Guthrie, W. et al. Accuracy of Autism Screening in a Large Pediatric Network. *Pediatrics* **144** (2019).
- [24] Satterstrom, F. K. et al. Large-scale exome sequencing study implicates both developmental and functional changes in the neurobiology of autism. *bioRxiv* (2019). <https://www.biorxiv.org/content/early/2019/04/24/484113.full.pdf>.
- [25] Sandin, S. et al. The Heritability of Autism Spectrum DisorderReassessing the Heritability of Autism Spectrum DisordersLetters. *JAMA* **318**, 1182–1184 (2017). URL <https://doi.org/10.1001/jama.2017.12141>. [https://jamanetwork.com/journals/jama/articlepdf/2654804/jama\\_sandin\\_2017\\_id\\_170037.pdf](https://jamanetwork.com/journals/jama/articlepdf/2654804/jama_sandin_2017_id_170037.pdf).
- [26] Ohja, K. et al. Neuroimmunologic and Neurotrophic Interactions in Autism Spectrum Disorders: Relationship to Neuroinflammation. *Neuromolecular Med.* **20**, 161–173 (2018).
- [27] Gadysz, D., Krzywdziska, A. & Hozyasz, K. K. Immune Abnormalities in Autism Spectrum Disorder-Could They Hold Promise for Causative Treatment? *Mol. Neurobiol.* **55**, 6387–6435 (2018).
- [28] Sanders, S. J. et al. Insights into Autism Spectrum Disorder Genomic Architecture and Biology from 71 Risk Loci. *Neuron* **87**, 1215–1233 (2015).
- [29] Gaugler, T. et al. Most genetic risk for autism resides with common variation. *Nat. Genet.* **46**, 881–885 (2014).
- [30] Werling, D. M. The role of sex-differential biology in risk for autism spectrum disorder. *Biol Sex Differ* **7**, 58 (2016).
- [31] Abrahams, B. S. & Geschwind, D. H. Advances in autism genetics: on the threshold of a new neurobiology. *Nat. Rev. Genet.* **9**, 341–355 (2008).
- [32] Yamashita, Y. et al. Anti-inflammatory Effect of Ghrelin in Lymphoblastoid Cell Lines From Children With Autism Spectrum Disorder. *Front Psychiatry* **10**, 152 (2019).
- [33] Shen, L. et al. Proteomics Study of Peripheral Blood Mononuclear Cells (PBMCs) in Autistic Children. *Front Cell Neurosci* **13**, 105 (2019).
- [34] Theoharides, T. C., Tsilioni, I., Patel, A. B. & Doyle, R. Atopic diseases and inflammation of the brain in the pathogenesis of autism spectrum disorders. *Transl Psychiatry* **6**, e844 (2016).
- [35] Young, A. M. et al. From molecules to neural morphology: understanding neuroinflammation in autism spectrum condition. *Mol Autism* **7**, 9 (2016).
- [36] Croen, L. A. et al. Family history of immune conditions and autism spectrum and developmental disorders: Findings from the study to explore early development. *Autism Res* **12**, 123–135 (2019).
- [37] Zerbo, O. et al. Immune mediated conditions in autism spectrum disorders. *Brain Behav. Immun.* **46**, 232–236 (2015).

- [38] Miotto, R., Li, L., Kidd, B. A. & Dudley, J. T. Deep Patient: An Unsupervised Representation to Predict the Future of Patients from the Electronic Health Records. *Sci Rep* **6**, 26094 (2016).
- [39] Glatt, S. J. et al. Blood-based gene expression signatures of infants and toddlers with autism. *J Am Acad Child Adolesc Psychiatry* **51**, 934–944 (2012).
- [40] Prampano, T. et al. Prediction of autism by translation and immune/inflammation coexpressed genes in toddlers from pediatric community practices. *JAMA Psychiatry* **72**, 386–394 (2015).
- [41] Hu, V. W. & Lai, Y. Developing a Predictive Gene Classifier for Autism Spectrum Disorders Based upon Differential Gene Expression Profiles of Phenotypic Subgroups. *N Am J Med Sci (Boston)* **6** (2013).
- [42] Kong, S. W. et al. Characteristics and predictive value of blood transcriptome signature in males with autism spectrum disorders. *PLoS ONE* **7**, e49475 (2012).
- [43] Hansen, L. The truven health marketscan databases for life sciences researchers. *Truven Health Analytics IBM Watson Health* (2017).
- [44] Granger, C. W. J. & Joyeux, R. An introduction to long-memory time series models and fractional differencing. *Journal of Time Series Analysis* **1**, 15–29.
- [45] Chattopadhyay, I. & Lipson, H. Abductive learning of quantized stochastic processes with probabilistic finite automata. *Philos Trans A* **371**, 20110543 (2013). URL <http://rsta.royalsocietypublishing.org/content/371/1984/20110543.full.pdf>.
- [46] Stoyanov, S. V., Racheva-Iotova, B., Rachev, S. T. & Fabozzi, F. J. Stochastic models for risk estimation in volatile markets: a survey. *Annals of Operations Research* **176**, 293–309 (2010). URL <https://doi.org/10.1007/s10479-008-0468-1>.
- [47] Shumway, R. H. & Stoffer, D. S. *Time Series Regression and ARIMA Models*, 89–212 (Springer New York, New York, NY, 2000). URL [https://doi.org/10.1007/978-1-4757-3261-0\\_2](https://doi.org/10.1007/978-1-4757-3261-0_2).
- [48] General equivalence mappings. URL [https://www.cms.gov/Medicare/Coding/ICD10/downloads/ICD-10\\_GEM\\_fact\\_sheet.pdf](https://www.cms.gov/Medicare/Coding/ICD10/downloads/ICD-10_GEM_fact_sheet.pdf).
- [49] Cover, T. M. & Thomas, J. A. *Elements of Information Theory* (Wiley Series in Telecommunications and Signal Processing) (Wiley-Interscience, New York, NY, USA, 2006).
- [50] Kullback, S. & Leibler, R. A. On information and sufficiency. *Ann. Math. Statist.* **22**, 79–86 (1951). URL <https://doi.org/10.1214/aoms/1177729694>.
- [51] Doob, J. *Stochastic Processes*. Wiley Publications in Statistics (John Wiley & Sons, 1953). URL <https://books.google.com/books?id=KvJQAAAAMAAJ>.
- [52] Friedman, J. H. Stochastic gradient boosting. *Comput. Stat. Data Anal.* **38**, 367–378 (2002). URL [http://dx.doi.org/10.1016/S0167-9473\(01\)00065-2](http://dx.doi.org/10.1016/S0167-9473(01)00065-2).